Emergent Biosolutions (EBS) said Thursday it was awarded a $41.9 million research and development option by the Biomedical Advanced Research and Development Authority to back the scale-up program of Ebola treatment Ebanga.
The existing 10-year contract has a base period of performance with two option periods for advanced development valued at about $121 million, the company said, adding option periods for procurement of Ebanga over five years are valued at up to $583 million.
Under the contract, Emergent has to complete activities to advance the development of Ebanga via post-licensure commitments, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。